You are here

Therapeutic Advances in Hematology

Therapeutic Advances in Hematology

Other Titles in:
Hematologic Disorders | Hematology

eISSN: 20406215 | ISSN: 20406207 | Current volume: 14 | Current issue: 1 Frequency: Yearly

Journal Highlights

  • Launched in 2010.
  • Gold open access journal – all articles are made freely available online immediately upon publication.
  • Robust peer review.
  • Listed in PubMed and indexed in Scopus and Science Citation Index Expanded (SCIE).
  • Over 200,000 full-text article views annually.

Therapeutic Advances in Hematology (TAH) is a peer-reviewed open access journal which focuses on delivering the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of hematology. Please see the Aims and Scope tab for further information.

The journal is a member of the Committee on Publication Ethics (COPE).

This journal flipped to open access on July 1, 2018.

Diversity, Equity and Inclusion Statement

TAH promotes inclusive, open science that reflects the disciplinary, human, and geographic diversity of the hematology community.

Diversity as a core value embodies inclusiveness, mutual respect, and multiple perspectives.

We welcome editors, editorial board members, peer reviewers and authors from all backgrounds, cultures, ethnicities, nationalities, races, religions, sexes, sexual orientations, gender identities, mental or physical (dis)abilities, ages, career stages, socio-economic status or any other individual status.

We are committed to continually improving our editorial and review processes whilst playing our part in eradicating bias and inequality in all forms.

Submission information

Submit your manuscript today at

Please see the Submission Guidelines tab for more information on how to submit your article to the journal.

Open access information

Unsolicited manuscripts submitted to TAH are subject to an article processing charge (APC) of USD 2650 (+VAT where applicable) payable upon acceptance. The article processing charge for Plain Language Summary is $4500. These articles will be published under a Creative Commons licence and will be made openly available.

The APC is payable when a manuscript is accepted after peer review, before it is published. The APC is subject to taxes where applicable. Please see further details here.


Please direct any enquiries to

This journal changed its publication mode from subscription to open access in 2019.

Therapeutic Advances in Hematology delivers the highest quality peer-reviewed open access original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of blood disorders. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in hematology and related disciplines, providing an online forum for rapid dissemination of recent research and perspectives in this area.

The journal is dedicated to publishing clinical research. We do not publish preclinical research, including basic laboratory research and animal studies.

Review articles include expert opinion/perspective reviews (including single-drug and drug class reviews), narrative reviews and therapeutic area reviews. Systematic reviews, meta-analyses, postmarketing and health economic and pharmacoeconomic reviews are also welcomed. The appropriate EQUATOR Network reporting guidelines should be followed (e.g. CONSORT for randomized, controlled trials and PRISMA for systematic reviews/meta-analyses). The journal endorses the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment. However, consistent with the AllTrials campaign, retrospectively registered trials will be considered if the justification for late registration is acceptable.

The journal adheres to a single-anonymised peer review process in which the reviewer's name is routinely withheld from the author unless the reviewer requests a preference for their identity to be revealed. Manuscripts are reviewed by at least two referees; online publication is usually within three weeks of Acceptance.

Associate Editors
Elisabetta Abruzzese, MD, PhD S. Eugenio Hospital, Tor Vergata University, Rome, Italy
Cedric Hermans, MD, PhD, FRCP (Lon, Edin) St-Luc University Hospital, Brussels, Belgium
Elias Jabbour, MD M.D. Anderson Cancer Center, Houston, TX, USA
Wojciech Jurczak, MD, PhD Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland
Michaela Liedtke, MD Stanford Cancer Institute, Stanford, CA, USA
Sarah Tasian, MD Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
Diversity, Equity, and Inclusion Ambassador
Raymona Lawrence, CDE, MPH, DrPH Georgia Southern University, USA
Editorial Board
Pratima Chowdary, MD, FRCPath Royal Free Hospital NHS Foundation Trust, London, UK
Graham Collins, MD, PhD Oxford University Hospitals, Oxford, UK
Jorge Cortes, MD M.D. Anderson Cancer Center, Houston, TX, USA
Myron Czuczman, MD Citius Pharmaceuticals, Inc., Cranford, NJ, United States
Christopher Edwards, PhD North Carolina Central University, USA
Elliot Epner, MD CompHealth, United States
Alessandra Ferrajoli, MD M.D. Anderson Cancer Center, Houston, TX, USA
Guillermo Garcia-Manero, MD M.D. Anderson Cancer Center, Houston, TX, USA
Amy Geddis, MD, PhD Seattle Children’s Hospital, Washington, WA, USA
David Gómez-Almaguer, MD, FACP Universidad Autónoma de Nuevo León: San Nicolás De Los Garza, Nuevo León, Mexico
Katharina Gotze, MD Technical University of Munich, Munich, Germany
Eric Grabowski, MD, ScD Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
Elizabeth Hexner, MD, MSTR Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA
Ulrich Keller, MD Technical University of Munich, Munich, Germany
Karl-Anton Kreuzer University of Cologne, Germany
Hillard Lazarus, MD, FACP Case Western Reserve University, Cleveland, OH, USA
Georg Lenz, MD University Hospital Münster, Münster, Germany
Howard Liebman, MD University of Southern California - Keck School of Medicine, Los Angeles, CA, USA
Eduardo Olavarria, MD, PhD Imperial College London at hammersmith Hospital, London, UK
Johnny N. Mahlangu, MMed, FCPath, MBBCh, BSc University of the Witwatersrand and National Health Laboratory Service, Johannesburg, South Africa
Pier Mannuccio Mannucci, MD Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy
Keith McCrae, MD Case Western Reserve University, Cleveland Clinic, Cleveland, OH, USA
Neha Mehta-Shah, MD Washington University Medical School, St. Louis, MO, USA
Guillermo Montalban Bravo, MD University of Texas,MD Anderson Cancer Center, Houston, TX, USA
Stephen Oh Washington University School of Medicine, St. Louis, MO, USA
Ifeyinwa Osunkwo, Md, MPH Emory University School of Medicine, Atlanta, USA
Gaël Roué, PhD Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Spain
Bipin Savani Vanderbilt University Medical Center, Nashville, TN, USA
Raymond SM Wong, MD, MRCP, FHKCP, FHKAM, MBChB The Chinese University of Hong Kong (CUHK), Hong Kong, CN
Peter Valent, MD Medical University of Vienna, Vienna, Austria
Alessandro Vannucchi, MD University of Florence, Florence, Italy
Nikolas von Bubnoff, MD Freiburg University Medical Center, Freiburg, Germany
Jianxiang Wang, MD Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, China
Guy Young, MD University of Southern California-Keck School of Medicine, Los Angeles, CA, USA
Managing Editor
Bushra Mahdi Sage Publications Ltd, United Kingdom
Biostatistical Editors
Daniel Diaz, PhD Universidad Nacional Autónoma de México,Mexico City, Mexico
Massimo Milani, MD MedicalDepartment, Cantabria Labs Difa Cooper, Caronno, VA, Italy
Elisabetta Petracci, PhD Istituto scientifico Romagnolo per lo Studio e la Cura dei tumori (IRST) IRCCS, Meldola, Italy
Andrea Ripoli, PhD Fondazione Toscana Gabriele Monasterio, Pisa, Italy
Tim Spelman, MBBS, PhD, BSc Burnet Institute, Melbourne, Australia
Editorial Review Board
Ibrahim Aldos, MD City of Hope National Cancer Center, Duarte, California, USA
Harinder Gill, MBBS, MD, FRCP, FRCPath The University of Hong Kong, Hong Kong
Assistant Managing Editors
Aakshi Kainthola Sage Publishing, Dehradun, India
Sakshi Malhotra Sage Publications Ltd, India
Peer Review Assistant
Nidhi Manori Sage Publications Ltd, India
  • Clarivate Analytics: Current Contents - Life Sciences
  • Clarivate Analytics: Science Citation Index Expanded (SCIE)
  • Directory of Open Access Journals (DOAJ)
  • ProQuest
  • PubMed Central (PMC)
  • Scopus
  • Manuscript submission guidelines can be accessed on Sage Journals.